CSO Dr Daniel Tillett talks to Small Caps about Race Oncology’s Plans for 2022 and beyond
Race Oncology Q&A Session
Race Oncology Investor Presentation November 2021
Race Oncology Share Purchase Plan Explained
Race Oncology AGM 2021 Presentation with Share Purchase Program Details
Race Oncology reveals breakthrough chemotherapy heart protection discovery for Zantrene
MST Access Investor Conference Presentation
MST Access Investor Conference Presentation
Race Oncology’s Mr Phil Lynch (CEO & MD) and Dr Daniel Tillett (CSO & ED) presented to the MST Access Australian Micro & Small Caps Conference 2021 on the 17th June 2021....
Race Oncology May 2021 Investor Update
Race Oncology May 2021 Investor Update
Race Oncology updates our shareholders on our progress and clinical plans for 2021 and beyond....
Race Oncology’s 2020 AGM
Race Oncology’s 2020 AGM
Race Oncology Limited (ASX: RAC) is pleased to release an extended version of the presentation from our 2020 Annual General Meeting (AGM). Race’s Managing Director and CEO, Mr Phil Lynch commented, “At the time...
Race team talks about new leadership model
Race team talks about new leadership model
Our executive leaders discuss the benefits of a shared leadership model and the experience they each bring to Race Oncology....
